09. 10.15 16:25 Close share menu KEYTRUDA (Pembrolizumab) for first-line treatment of advanced melanoma receives new draft of the recommendation by the National Institute for health and care Excellence (NICE) in the United Kingdom Source FinanzNachrichten.de Close share menu